Phase I Trial of Consolidative Radiotherapy with Concurrent Bevacizumab, Erlotinib and Capecitabine for Unresectable Pancreatic Cancer

PURPOSE: To determine the safety, tolerability and maximum tolerated dose (MTD) of addition of erlotinib to bevacizumab and capecitabine-based definitive chemoradiation (CRT) in unresectable pancreatic cancer. METHODS: Seventeen patients with CT-staged, biopsy-proven unresectable pancreatic cancer w...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :PLoS One
Главные авторы: Chadha, Awalpreet S., Skinner, Heath D., Gunther, Jillian R., Munsell, Mark F., Das, Prajnan, Minsky, Bruce D., Delclos, Marc E., Chatterjee, Deyali, Wang, Huamin, Clemons, Marilyn, George, Geena, Singh, Pankaj K., Katz, Matthew H., Fleming, Jason B., Javle, Milind M., Wolff, Robert A., Varadhachary, Gauri R., Crane, Christopher H., Krishnan, Sunil
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2016
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4919049/
https://ncbi.nlm.nih.gov/pubmed/27336466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0156910
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы